Table 2.
Ongoing GLP-1R agonist clinical trials in PD patients.
| Title | ClinicalTrials.gov ID | Phase | Status | Intervention | Results Overview |
|---|---|---|---|---|---|
| Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson’s Disease (Exenatide-PD3) | NCT04232969 | Phase 3 | Active, not recruiting | Drug: Exenatide extended release 2 mg (Bydureon) | Result not yet available |
| Effects of Exenatide on Motor Function and the Brain | NCT03456687 | Phase 1 | Completed | Drug: Exenatide | No result available |
| Exenatide Treatment in Parkinson’s Disease | NCT04305002 | Phase 2 | Active, not recruiting | Drug: Exenatide Other: Placebo | No result available |
| SR-Exenatide (PT320) to Evaluate Efficacy and Safety in Patients With Early Parkinson’s Disease | NCT04269642 | Phase 2 | Active, not recruiting | Drug: PT320 2.0 mg Placebo Drug: PT320 2.0 mg Drug: PT320 2.5 mg |
Unknown status |
| GLP1R in Parkinson’s Disease (GIPD) | NCT03659682 | Phase 2 | Not yet recruiting | Drug: Semaglutide | No result available |
| A Clinical Study of NLY01 in Patient’s With Early Parkinson’s Disease | NCT04154072 | Phase 2 | Active, not recruiting | Drug: NLY01 Drug: Vehicle |
No result available |